Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $1.0 billion.

  • Janux Therapeutics' Liabilities and Shareholders Equity rose 47.44% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 69.77%. This contributed to the annual value of $1.1 billion for FY2024, which is 179.05% up from last year.
  • Per Janux Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $1.0 billion for Q3 2025, which was down 0.72% from $1.0 billion recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Liabilities and Shareholders Equity peaked at $1.1 billion during Q4 2024, and registered a low of $341.5 million during Q2 2023.
  • In the last 3 years, Janux Therapeutics' Liabilities and Shareholders Equity had a median value of $691.4 million in 2024 and averaged $700.6 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 2,242.13% in 2021, then decreased by 11.38% in 2023.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Liabilities and Shareholders Equity stood at $379.8 million in 2021, then dropped by 4.16% to $364.0 million in 2022, then grew by 4.50% to $380.4 million in 2023, then surged by 179.05% to $1.1 billion in 2024, then soared by 47.44% to $1.0 billion in 2025.
  • Its last three reported values are $1.0 billion in Q3 2025, $1.0 billion for Q2 2025, and $1.1 billion during Q1 2025.